GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » E10

Galectin Therapeutics (Galectin Therapeutics) E10

: $-0.72 (As of Dec. 2023)
View and export this data going back to 2002. Start your Free Trial

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Galectin Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.72 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 3.00% per year. During the past 5 years, the average E10 Growth Rate was 4.50% per year. During the past 10 years, the average E10 Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Galectin Therapeutics was 7.90% per year. The lowest was 2.80% per year. And the median was 6.15% per year.

As of today (2024-04-19), Galectin Therapeutics's current stock price is $3.37. Galectin Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-0.72. Galectin Therapeutics's Shiller PE Ratio of today is .


Galectin Therapeutics E10 Historical Data

The historical data trend for Galectin Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.86 -0.79 -0.77 -0.79 -0.72

Galectin Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -0.80 -0.73 -0.73 -0.72

Competitive Comparison

For the Biotechnology subindustry, Galectin Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Shiller PE Ratio falls into.



Galectin Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galectin Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.16/129.4194*129.4194
=-0.160

Current CPI (Dec. 2023) = 129.4194.

Galectin Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -0.270 99.695 -0.351
201406 -0.170 100.560 -0.219
201409 -0.170 100.428 -0.219
201412 -0.180 99.070 -0.235
201503 -0.220 99.621 -0.286
201506 -0.210 100.684 -0.270
201509 -0.260 100.392 -0.335
201512 -0.190 99.792 -0.246
201603 -0.240 100.470 -0.309
201606 -0.200 101.688 -0.255
201609 -0.160 101.861 -0.203
201612 -0.160 101.863 -0.203
201703 -0.150 102.862 -0.189
201706 -0.140 103.349 -0.175
201709 -0.130 104.136 -0.162
201712 -0.070 104.011 -0.087
201803 -0.120 105.290 -0.148
201806 -0.110 106.317 -0.134
201809 -0.070 106.507 -0.085
201812 -0.080 105.998 -0.098
201903 -0.200 107.251 -0.241
201906 -0.060 108.070 -0.072
201909 -0.050 108.329 -0.060
201912 -0.120 108.420 -0.143
202003 -0.060 108.902 -0.071
202006 -0.110 108.767 -0.131
202009 -0.100 109.815 -0.118
202012 -0.130 109.897 -0.153
202103 -0.110 111.754 -0.127
202106 -0.150 114.631 -0.169
202109 -0.140 115.734 -0.157
202112 -0.120 117.630 -0.132
202203 -0.170 121.301 -0.181
202206 -0.160 125.017 -0.166
202209 -0.140 125.227 -0.145
202212 -0.180 125.222 -0.186
202303 -0.190 127.348 -0.193
202306 -0.150 128.729 -0.151
202309 -0.240 129.860 -0.239
202312 -0.160 129.419 -0.160

Add all the adjusted EPS together and divide 10 will get our e10.


Galectin Therapeutics  (NAS:GALT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Galectin Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics (Galectin Therapeutics) Business Description

Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Executives
Kary Eldred director 2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman director 712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr. director 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
10x Fund, L.p. 10 percent owner 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz director 235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio director 5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein director, 10 percent owner 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes officer: Chief Medical Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Joel Lewis director 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin director, officer: Chief Executive Officer C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt officer: Chief Financial Officer 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
James C Czirr director 4908 SOUTH ASHTON COURT, SPOKANE WA 99223
Peter G Traber director, officer: President and CEO 430 THAMER LANE, HOUSTON TX 77025

Galectin Therapeutics (Galectin Therapeutics) Headlines

From GuruFocus